Lichenoid drug eruption induced by propanolol

Hawk, J.L.M.

doi:10.1111/j.1365-2230.1980.tb01673.x

Cited by 46 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma viscosity was raised at 1-82 cp (normal 1-5-1 72). Serum alkaline phosphatase was raised at 15 KA units (normal [3][4][5][6][7][8][9][10][11][12][13] with a slight increase of the hepatic free fraction on isoenzyme analysis; liver function tests were otherwise normal. Autoimmune profile was negative apart from weakly positive antibodies to gastric parietal cells, intrinsic factor antibodies being negative.…”

Section: Investigationmentioning

confidence: 99%

Exfoliative dermatitis due to nifedipine

et al. 1989

View full text Add to dashboard Cite

show abstract

Section: Investigationmentioning

confidence: 99%

Exfoliative dermatitis due to nifedipine

et al. 1989

View full text Add to dashboard Cite

show abstract

“…However, there are only a few case reports on one or two patients that implicate the usage of BABs with the development of oral lichen planus lesions in these individuals. Cutaneous as well as oral lesions have been reported in a patient taking propranolol (Hawk, 1980). In this patient, therapy including propranolol (240 mg a day; S for CYP1A2, 2C9, 2D6) and furosemide (80 mg a day) was initiated 21 months prior to the onset of reaction.…”

Section: Beta-adrenergic Blockers (Babs) (Anti-arrhythmics Class Ii)mentioning

confidence: 99%

Oral Adverse Drug Reactions to Cardiovascular Drugs

Torpet

Kragelund

Reibel

et al. 2004

Critical Reviews in Oral Biology & Medicine

View full text Add to dashboard Cite

A great many cardiovascular drugs (CVDs) have the potential to induce adverse reactions in the mouth. The prevalence of such reactions is not known, however, since many are asymptomatic and therefore are believed to go unreported. As more drugs are marketed and the population includes an increasing number of elderly, the number of drug prescriptions is also expected to increase. Accordingly, it can be predicted that the occurrence of adverse drug reactions (ADRs), including the oral ones (ODRs), will continue to increase. ODRs affect the oral mucous membrane, saliva production, and taste. The pathogenesis of these reactions, especially the mucosal ones, is largely unknown and appears to involve complex interactions among the drug in question, other medications, the patient's underlying disease, genetics, and life-style factors. Along this line, there is a growing interest in the association between pharmacogenetic polymorphism and ADRs. Research focusing on polymorphism of the cytochrome P450 system (CYPs) has become increasingly important and has highlighted the intra-and inter-individual responses to drug exposure. This system has recently been suggested to be an underlying candidate regarding the pathogenesis of ADRs in the oral mucous membrane. This review focuses on those CVDs reported to induce ODRs. In addition, it will provide data on specific drugs or drug classes, and outline and discuss recent research on possible mechanisms linking ADRs to drug metabolism patterns. Abbreviations used will be as follows:

show abstract

“…Treatment includes drug discontinuation and topical steroids. Lichenoid drug eruptions have been reported with carbamazepine, 110,111 phenothiazines, 112,113 propranolol, 114,115 lithium 116 and lorazepam 117…”

Section: Other Adverse Cutaneous Reactionsmentioning

confidence: 99%